Back to Trial

Oracle Runs

Oracle findings and outcome history for A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) (NCT06881251).

Runs
2
Findings
2
Latest Run
Apr 3, 2026, 4:30 PM
Resolution Evidence
Outcome
NO
Status
Resolved
Settlement Date
4/3/26 UTC
Executive Summary

Exact-trial evidence is negative. J&J’s public statement on DUPLEX-AD says the planned interim analysis triggered early termination because the study did not meet the efficacy bar for advancing in atopic dermatitis. ClinicalTrials.gov identifies DUPLEX-AD as NCT06881251.

Sources
Sponsorjnj.com12/26/25
Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study

J&J said the Phase 2b DUPLEX-AD interim analysis met criteria for early termination because it did not meet the efficacy bar set for advancing its atopic dermatitis program.

View source
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06881251 | A Study of JNJ-95475939 in Moderate to Severe Atopic Dermatitis

ClinicalTrials.gov identifies NCT06881251 as the DUPLEX-AD study evaluating JNJ-95475939 in moderate to severe atopic dermatitis.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NOAccepted98% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Exact-trial evidence is negative. J&J’s public statement on DUPLEX-AD says the planned interim analysis triggered early termination because the study did not meet the efficacy bar for advancing in atopic dermatitis. ClinicalTrials.gov identifies DUPLEX-AD as NCT06881251.

Found Apr 3, 2026, 4:30 PMOutcome date Dec 26, 2025, 12:00 AMReviewed Apr 3, 2026, 5:19 PM
Sponsorjnj.comDec 26, 2025, 12:00 AM
Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study
J&J said the Phase 2b DUPLEX-AD interim analysis met criteria for early termination because it did not meet the efficacy bar set for advancing its atopic dermatitis program.
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06881251 | A Study of JNJ-95475939 in Moderate to Severe Atopic Dermatitis
ClinicalTrials.gov identifies NCT06881251 as the DUPLEX-AD study evaluating JNJ-95475939 in moderate to severe atopic dermatitis.
NORejected97% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

NCT06881251 is the DUPLEX-AD study/identifier 95475939ADM2001. J&J publicly said the planned interim analysis triggered early termination because the study did not meet the efficacy bar for advancing in atopic dermatitis. That is a clearly negative trial-specific readout.

Found Apr 1, 2026, 7:52 PMOutcome date Dec 26, 2025, 12:00 AMReviewed Apr 1, 2026, 7:55 PM
Sponsorjnj.comDec 26, 2025, 12:00 AM
Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study
J&J said the Phase 2b DUPLEX-AD study of JNJ-95475939 met criteria for early termination because results did not meet the efficacy bar set for advancing the AD program.
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06881251 | A Study of JNJ-95475939 in Moderate to Severe Atopic Dermatitis
ClinicalTrials.gov identifies NCT06881251 as DUPLEX-AD and lists other identifier 95475939ADM2001, matching the J&J statement.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle ReviewApr 3, 2026, 5:19 PM

Will the results be positive?

PendingtoNOcurrentNO
GPT-5.4 (OpenAI)98% confidenceReviewed Apr 3, 2026, 5:19 PM

Exact-trial evidence is negative. J&J’s public statement on DUPLEX-AD says the planned interim analysis triggered early termination because the study did not meet the efficacy bar for advancing in atopic dermatitis. ClinicalTrials.gov identifies DUPLEX-AD as NCT06881251.